When a blood vessel in the brain becomes blocked, a cascade of harmful events unfolds rapidly. Cells are starved of oxygen, immune cells surge in, and neurons begin to die through a process called apoptosis. Even when blood flow is restored, a wave of inflammation can extend the damage further. Researchers have spent decades looking for compounds that might interrupt this cascade.
A study published in Neurochemical Research explored whether combining two compounds, elamipretide (also known as SS-31) and nicotinamide mononucleotide (NMN), could protect brain tissue in mice that had experienced a simulated stroke. Each compound was already known to have neuroprotective properties, but the researchers wanted to know whether pairing them would add up to something greater than the sum of their parts.
The short answer from the data was yes. But the more interesting finding was the molecular explanation for why, centering on a protein called TREM2 that sits at the intersection of brain inflammation and cell death.
The stroke model and why it matters
The research team used a well-established laboratory technique called middle cerebral artery occlusion and reperfusion, shortened to MCAO/R. In this model, blood flow to a key region of the mouse brain is temporarily blocked and then restored, closely mimicking the pattern seen in human ischemic strokes followed by treatment.
This model is important because it captures two phases of injury. The first is the initial damage from lack of oxygen. The second, sometimes called reperfusion injury, occurs when blood returns and triggers an intense inflammatory response. Many promising stroke treatments in the lab have stumbled in clinical translation partly because they only address one of these phases.
Male mice received one of four treatment conditions: SS-31 alone, NMN alone, both together, or no treatment. Researchers then measured neurobehavioral scores, examined brain tissue under the microscope, ran whole-genome transcriptomic sequencing to see which genes changed, and analyzed protein levels tied to inflammation and cell survival.
What each compound does on its own
Elamipretide, the peptide compound designated SS-31, targets the inner membrane of mitochondria, the energy-producing structures inside cells. Mitochondria are among the first casualties of stroke-related oxygen deprivation, and protecting them from early damage is thought to preserve overall cell function. The literature suggests SS-31 helps stabilize mitochondrial membranes and reduce the release of molecules that trigger further cell death.
NMN is a precursor to a molecule called NAD+, which plays a central role in cellular energy metabolism and the activity of proteins that regulate gene expression and DNA repair. NAD+ levels tend to fall sharply after ischemic injury, and the literature suggests that restoring them through NMN supplementation can support cell survival pathways.
Because these two compounds act through different mechanisms, one at the mitochondrial membrane and one at the level of metabolic cofactors, the research team hypothesized that using both at once might produce broader protection than either could achieve alone.
The TREM2 connection
The most novel finding in the study centered on a protein called TREM2, which stands for triggering receptor expressed on myeloid cells 2. TREM2 is found on microglia, the immune cells of the brain. Under normal conditions microglia act as housekeepers, clearing debris and monitoring for threats. After a stroke, they can shift into an inflammatory state that amplifies damage.
Transcriptomic sequencing, which reads the activity levels of thousands of genes at once, revealed that the combination therapy specifically reduced TREM2 expression in ways that neither compound achieved alone. This reduction was tied to changes in the innate immune and apoptotic pathways that were clearly visible in the gene-expression data.
To confirm that TREM2 was genuinely driving the outcome rather than just changing alongside it, the researchers conducted a separate experiment in which they forced TREM2 to be overexpressed in the mice. When TREM2 was artificially elevated, all of the neuroprotective benefits of the combination therapy disappeared. This reversal is a strong piece of evidence that TREM2 suppression is not a side effect of the treatment but a core part of how it works.
The NF-kB pathway as the upstream switch
Digging one layer deeper, the study found that the combination therapy reduced TREM2 by first inhibiting a well-known inflammatory signaling protein called NF-kB, specifically its p65 subunit. NF-kB acts like a master switch for inflammation in many cell types. When it is active, it drives production of pro-inflammatory molecules. When it is suppressed, that downstream cascade quiets down.
In this study, quieting NF-kB led to lower TREM2 levels, which in turn reduced microglial activation and decreased the production of three key inflammatory cytokines: IL-1 beta, TNF-alpha, and IL-6. These cytokines are known contributors to secondary brain injury in the hours and days after a stroke.
The researchers also examined the balance between two proteins that govern whether a cell lives or dies, called Bcl-2 and Bax. A higher ratio of Bcl-2 to Bax generally favors cell survival. The combination therapy shifted this ratio toward survival, suggesting it was reducing apoptosis alongside inflammation. Pharmacological inhibition of the NF-kB pathway produced similar results, reinforcing that this is the upstream node the combination is acting through.
Measured outcomes in the mice
Neurobehavioral scores, which assess things like limb use, body symmetry, and spontaneous activity in mice, improved significantly in the combination group compared to monotherapy or no treatment, with a p-value below 0.0001, meaning the result was highly unlikely to be due to chance alone.
Histopathological staining, which involves examining thin slices of brain tissue under a microscope, showed reduced tissue damage in the combination group. The size and severity of the injured region were smaller, and markers of cell death were less prominent.
The study authors noted that the effects were described as markedly superior to either monotherapy, a phrase the data appeared to support across multiple measurement types. Early data points at the possibility that targeting the NF-kB/TREM2 axis simultaneously through mitochondrial protection and metabolic support could be a genuinely additive approach in the preclinical setting.
Limitations and the road to further research
Mouse models of stroke, while valuable for understanding mechanisms, do not always translate cleanly to human biology. The MCAO/R model approximates certain features of human stroke but cannot capture the full complexity of cerebrovascular disease in a living person. The study used male mice only, which means sex-based differences in response remain unexplored.
Dosing, timing, and delivery route are also variables that would need extensive investigation before any of these findings could inform clinical thinking. The study does not provide guidance on what doses or schedules would be relevant outside the specific laboratory conditions used.
What the research does offer is a detailed mechanistic map linking two distinct compounds to a single molecular target in the post-ischemic brain. The literature suggests this kind of multi-targeted approach, hitting the same damaging process from two different angles, may be worth pursuing in more complex models. For now, these findings represent a preclinical proof of concept that researchers and the broader neuroscience community can build on.
